Nutrition Intervention to Decrease Symptoms in Patients With Advanced Heart Failure by Lennie, Terry A. et al.
University of Kentucky
UKnowledge
Nursing Faculty Publications College of Nursing
4-2013
Nutrition Intervention to Decrease Symptoms in
Patients With Advanced Heart Failure
Terry A. Lennie
University of Kentucky, terry.lennie@uky.edu
Debra K. Moser
University of Kentucky, debra.moser@uky.edu
Martha J. Biddle
University of Kentucky, mjbidd0@uky.edu
Darlene Welsh
University of Kentucky, jdwels00@uky.edu
Geza G. Bruckner
University of Kentucky, gbruckn@uky.edu
See next page for additional authors
Right click to open a feedback form in a new tab to let us know how this document benefits you.
Follow this and additional works at: https://uknowledge.uky.edu/nursing_facpub
Part of the Cardiology Commons, Dietetics and Clinical Nutrition Commons, and the Nursing
Commons
This Article is brought to you for free and open access by the College of Nursing at UKnowledge. It has been accepted for inclusion in Nursing Faculty
Publications by an authorized administrator of UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu.
Repository Citation
Lennie, Terry A.; Moser, Debra K.; Biddle, Martha J.; Welsh, Darlene; Bruckner, Geza G.; Thomas, D. Travis; Rayens, Mary Kay; and
Bailey, Alison L., "Nutrition Intervention to Decrease Symptoms in Patients With Advanced Heart Failure" (2013). Nursing Faculty
Publications. 9.
https://uknowledge.uky.edu/nursing_facpub/9
Authors
Terry A. Lennie, Debra K. Moser, Martha J. Biddle, Darlene Welsh, Geza G. Bruckner, D. Travis Thomas,
Mary Kay Rayens, and Alison L. Bailey
Nutrition Intervention to Decrease Symptoms in Patients With Advanced Heart Failure
Notes/Citation Information
Published in Research in Nursing & Health, v. 36, issue 2, p. 120-145.
Copyright © 2013 Wiley Periodicals, Inc
This is the accepted version of the following article: Lennie, T. A., Moser, Debra. K., Biddle, M. J., Welsh, D.,
Bruckner, G. G., Thomas, D. T., Rayens, M. K. and Bailey, A. L. (2013), Nutrition intervention to decrease
symptoms in patients with advanced heart failure. Research in Nursing & Health, 36: 120-145, which has been
published in final form at https://doi.org/10.1002/nur.21524. This article may be used for non-commercial
purposes in accordance with Wiley Terms and Conditions for Self-Archiving.
Digital Object Identifier (DOI)
https://doi.org/10.1002/nur.21524
This article is available at UKnowledge: https://uknowledge.uky.edu/nursing_facpub/9
Nutrition Intervention to Decrease Symptoms in Patients With
Advanced Heart Failure
Terry A. Lennie1,*, Debra. K. Moser1,*, Martha J. Biddle1,**, Darlene Welsh1,**, Geza G.
Bruckner2,*, D. Travis Thomas2,**, Mary Kay Rayens1,*, and Alison L. Bailey3,**
1College of Nursing, University of Kentucky, 751 Rose Street, Lexington, KY 40536-0232
2Division of Clinical Nutrition, Department of Clinical Sciences, College of Health Sciences,
University of Kentucky, Lexington, KY 40536-0232
3Division of Cardiovascular Medicine, College of Medicine, University of Kentucky, Lexington, KY
40536-0232
Abstract
For a majority of patients with advanced heart failure, there is a need for complementary, non-
pharmacologic interventions that could be easily implemented by health care providers to provide
palliative care. Three major pathologic pathways underlying heart failure symptoms have been
identified: fluid overload, inflammation, and oxidative stress. Prior research has demonstrated that
three nutrients-sodium, omega-3 fatty acids, and lycopene-can alter these pathologic pathways.
Therefore, the purposes of this study are to test the effects of a 6-month nutrition intervention of
dietary sodium reduction combined with supplementation of lycopene and omega-3 fatty acids on
heart failure symptoms, health-related quality of life, and time to heart failure rehospitalization or
all-cause death. The aims of this double blind-placebo controlled study are (1) to determine the
effects of a 6-month nutrition intervention on symptom burden (edema, shortness of air, and
fatigue) and health-related quality of life at 3 and 6 months, and time to heart failure
rehospitalization or all-cause death over 12 months from baseline; (2) compare dietary sodium
intake, inflammation, and markers of oxidative stress between the nutrition intervention group and
a placebo group at 3 and 6 months; and (3) compare body weight, serum lycopene, and
erythrocyte omega-3 index between the nutrition intervention group and a placebo group at 3 and
6 months. A total of 175 patients with advanced heart failure will be randomized to either the
nutrition intervention or placebo group.
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Editor’s Note
In 1990, RINAH published an example of a successful R01 grant proposal to NINR and
excerpted critiques (Naylor, 1990). The application and review process has evolved since
that time, so we are pleased to present a successful proposal submitted and reviewed in the
current NIH application format, accompanied by NIH reviewer critiques. Submitted in
response to a call for proposals on advanced heart failure and palliative care, and funded by
NINR on its initial submission, this proposal is presented here with minimal editing. The
summary, scores, and overall impact statements of the study section critiques follow the
proposal, again with any errors or inconsistencies left intact. This article was handled as an
editorial and not peer reviewed by the journal. We are grateful to Dr. Lennie and colleagues
for sharing this work.
Specific Aims
The proposed study is in response to NIH Funding Opportunity RFA-11-006 Increasing
Opportunities in Advanced Heart Failure and Palliative Care Research. The study
addresses the following research initiative area of interest: Examine the impact of
interventions on symptom management with attention to symptom severity. Heart failure
ranks among the most costly health problems in terms of human suffering and health care
expenditures (Lloyd-Jones et al., 2010). It is a syndrome in which symptoms define the
diagnosis, severity, and determination of treatment effectiveness (Lindenfeld et al., 2010).
Thus, HF is considered a symptom-driven syndrome. Although privilege major advances in
medical management of HF over the past two decades have prolonged survival, patients
with advanced HF remain symptomatic after optimization of medical treatment (Hunt et al.,
2009). These symptoms are associated with frequent rehospitalizations and decreased
health-related quality of life (Heo, Moser, Lennie, Zambroski, & Chung, 2007). Current
guidelines call for symptomatic relief and palliative care to be incorporated into the ongoing
plan of care soon after diagnosis (Hunt et al., 2009). Combined, these observations indicate
the need for non-pharmacological interventions to decrease symptom severity and improve
quality of life that could be implemented as part of palliative care for patients with HF. We
developed a low cost, nutrition intervention to decrease the severity of the three most
common HF symptoms associated with frequent hospitalization and poor quality of life:
fluid overload/edema, shortness of air, and fatigue (Lindenfeld et al., 2010). The
intervention involves three nutrients that target the pathologic pathways underlying these HF
symptoms: sodium, omega-3 fatty acids, and lycopene.
Excess sodium intake is associated with fluid overload symptoms of edema and shortness of
air (Bennett et al., 1998; Chin & Goldman, 1997; Happ, Naylor, & Roe-Prior, 1997;
Hoskins, Walton-Moss, Clark, Schroeder, & Thiel, 1999; Michalsen, Konig, & Thimme,
1998; Opasich et al., 1996; Tsuyuki et al., 2001; Vinson, Rich, Sperry, Shah, & McNamara,
1990). We demonstrated that patients with advanced HF who consume higher (>3 g) sodium
diets have 2.5 times greater risk of rehospitalization than similar patients consuming lower
sodium diets (Lennie et al., 2011). Omega-3 fatty acids have beneficial anti-inflammatory
and anti-dysrhythmic effects (Tavazzi et al., 2008). We have shown that diets low in
omega-3 fatty acids in patients with HF are associated with high levels of the
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proinflammatory mediators (Lennie, Chung, Habash, & Moser, 2005) linked with symptoms
of fatigue and anorexia and altered myocardial and vascular endothelial function (Conraads,
Bosmans, & Vrints, 2002; Dantzer, 2009). Lycopene is a potent antioxidant (L. G. Rao,
Guns, & Rao, 2003) that plays a protective role against oxidative stress common in patients
with HF (Anker et al., 2003). Oxidative stress stimulates inflammation and impairs vascular
endothelial function leading to symptoms of edema, shortness of air, and fatigue (Doehner &
Anker, 2005). We have shown that diets of patients with HF low in lycopene are associated
with greater risk of hospitalization than diets higher in carotenoids, particularly lycopene
(Biddle et al., 2008).
To date, each of these nutrients has been individually demonstrated to have beneficial
effects. However, there is sound theoretical rationale (Fig. 1) that a combined intervention
targeting all three nutrients would have substantial benefit in relieving symptoms in
advanced HF. Therefore, the purposes of this study are to test the effects of a 6-month
nutrition intervention of dietary sodium reduction combined with supplemention of lycopene
and omega-3 fatty acids on HF symptoms, health-related quality of life, and time to HF
rehospitalization or all-cause death. Patients with advanced HF will be randomized to
intervention or placebo group and blinded to the group to which they are assigned. The
specific aims of this randomized, controlled, blinded trial are to:
1. Determine the effects of a 6-month nutrition intervention on symptom burden (i.e.,
edema, shortness of air, fatigue), health-related quality of life, and time to HF
rehospitalization or all-cause death over 12 months.
Hypothesis 1a: Symptom burden will be lower, and health related quality of life
will be higher in the nutrition intervention group than in the placebo group at
month 3 and 6 during the intervention and at 9 and 12 months (3 and 6 months after
the intervention).
Hypothesis 1b: Time to first event (HF rehospitalization or all-cause death) will be
longer in the nutrition intervention group than in the placebo group at the 12-month
time point.
2. Compare dietary sodium intake, markers of oxidative stress, and proinflammatory/
anti-inflammatory cytokine levels of patients in the nutrition intervention group
with those of patients in the placebo group at 3- and 6-month time points.
Hypothesis 2a: Dietary sodium intake (reflected by 24-hour urine sodium) will be
lower in the nutrition intervention than placebo group at the 3- and 6-month time
points.
Hypothesis 2b: Serum markers of oxidative stress (malondialdehyde and 8-iso-
PGF2a isoprostane) will be lower in the nutrition intervention than placebo group
at the 3- and 6-month time points.
Hypothesis 2c: Serum levels of proinflammatory markers (tumor necrosis factor-α
[TNF] and soluble TNF receptors: sTNFR1, and sTNFR2) will be lower and anti-
inflammatory cytokine interleukin-10 will be higher in the nutrition intervention
than placebo group at the 3- and 6-month time points.
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3. Compare the following markers of intervention adherence, fluid balance (body
weight), serum lycopene, and erythrocyte omega-3 index, at 3- and 6-month time
points between intervention and placebo groups.
Hypothesis 3. Intervention group will have stable body weights and higher serum
lycopene levels and erythrocyte omega-3 index than placebo group at 3- and 6-
month time points.
A. Significance
A1. Conceptual Framework
Figure 1 is the conceptual framework guiding our intervention. The proposed intervention
targets three major pathways underlying HF symptoms: fluid overload (depicted by short
dashed lines), oxidative stress (dotted lines), and inflammation (long dashed lines). The
symptoms produced by these pathways (solid lines) are primary reasons for HF (Heo et al.,
2007; Hunt et al., 2009). Fluid overload, the best known of the three pathways, is due to
compensatory neuroendocrine responses to decreased cardiac output that cause sodium and
fluid retention (Hunt et al., 2009). Consequently, limiting sodium in the diet has been a
mainstay of HF management for more than 60 years (Lennie, 2006). In the absence of diet
instruction and skill building, patients are not successful in implementing sodium-restricted
diets (Riegel et al., 2009). Our intervention is designed to provide patients with the
knowledge and skills needed to effectively limit dietary sodium. In the second pathway,
production of free oxygen radicals in response to hypoxia has two consequences (Doehner &
Anker, 2005). First, free radicals interact with nitric oxide (which plays a key role in
vasodilation) to produce cell damaging oxidants (Doehner & Anker, 2005). The subsequent
loss of nitric oxide bioavailability in vascular endothelium results in increased vascular
resistance, increased myocardial workload, and decreased cardiac output. Second, increased
free oxygen radical production can exceed the antioxidant capacity of cells (oxidative
stress), resulting in cellular damage that triggers inflammatory pathways (Anker et al.,
2003). The lycopene supplementation in the proposed intervention will enhance cell
antioxidant capacity thereby preserving endothelial nitric oxide, decreasing cell damage, and
minimizing stimulation of inflammatory pathways. The third pathway involves
proinflammatory cytokines which are elevated advanced HF (Conraads et al., 2002). These
cytokines cause myocardial dysfunction and myocyte apoptosis resulting in decreased
cardiac output (Ceconi, Curello, Bachetti, Corti, & Ferrari, 1998). Proinflammatory
cytokines also have systemic effects including decreased appetite and fatigue (Lennie,
1999). The omega-3 fatty acid supplementation component of the intervention targets the
inflammation pathway. Increasing omega-3 fatty acid content in cell membranes reduces
production of inflammatory mediators. In the myocardium, omega-3 fatty acids produce the
added benefit of decreasing cardiac dysrhythmias (Tavazzi et al., 2008).
A1.1. Heart Failure Symptoms, Quality of Life, Hospitalization, and Survival—
Heart failure is a clinical syndrome characterized by a constellation of signs and symptoms
(Hunt et al., 2009; Lindenfeld et al., 2010). Although medical treatment is aimed at
reversing neurohormone and other pathologic responses to decreased cardiac output, the
major target of treatment is HF symptom reduction (Hunt et al., 2009; Lindenfeld et al.,
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2010). The decision to add or adjust medications is commonly guided by persistence or
worsening of symptoms (Lindenfeld et al., 2010). Heart failure symptoms also drive
decisions regarding rehospitalization and discharge once hospitalized (Dickstein et al.,
2008). Data suggest that, after optimization of medications, 50% (Lee et al., 2009; Lennie et
al., 2011) to 85% (Jurgens et al., 2009) of patients with HF remain in New York Heart
Association (Lindenfeld et al., 2010; NYHA) functional Class III (experience symptoms
with less than ordinary activity) or Class IV (experience symptoms at rest). Dr. Moser and
colleagues have shown that unrelieved symptoms impact quality of life. Using the Memorial
Symptom Assessment Scale—Heart Failure and the Minnesota Living with Heart Failure
Questionnaire, they measured total symptom burden and quality of life of patients with HF,
respectively (Zambroski, Moser, Bhat, & Ziegler, 2005). The two symptoms with the
highest prevalence (85%) and greatest burden score (frequency + severity + distress) were
lack of energy and shortness of air. The strongest predictor of quality of life was symptom
burden, accounting for 22% of the variance. In other work, Moser and colleagues (Heo,
Doering, Widener, & Moser, 2008) reported comparable results when focusing only on
physical symptoms. Most patients reported experiencing symptoms of fatigue and shortness
of air daily. Similarly, physical symptoms were the strongest predictor of quality of life. In
summary, symptoms drive the diagnosis and treatment of HF.
For a majority of patients, medical treatment is only partially effective in relieving
symptoms. Unrelieved symptoms are related to low quality of life which, in turn, is a
predictor of both hospitalization and survival (Alla et al., 2002; Moser et al., 2009). There is
a clear need for complementary, non-pharmacologic, interventions that could be easily
included in palliative care to decrease symptoms in patients with advanced HF.
A2. Symptoms and Nutrition
There is evidence that nutrition could play a crucial role in influencing symptoms and HF
outcomes (Lennie, 2006; Lennie et al., 2005; Silver, 2003). Three nutrients, sodium,
lycopene, and omega-3 fatty acids, have been identified as having the potential to the three
major pathologic pathways, sodium/fluid retention, oxidative stress, and inflammation (Fig.
1).
A2.1. Fluid retention and sodium—Heart failure triggers a compensatory
neurohormone response that includes release of aldosterone, angiotensin, and vasopressin
(antidiuretic hormone), which cause sodium and fluid retention resulting in symptoms of
fluid overload (Lindenfeld et al., 2010). Excess sodium intake has been implicated in a
number of studies (Bennett et al., 1998; Chin & Goldman, 1997; Happ et al., 1997; Hoskins
et al., 1999; Michalsen et al., 1998; Opasich et al., 1996; Tsuyuki et al., 2001; Vinson et al.,
1990) to be the precipitating factor for the majority of hospital admissions due to symptoms
of decompensated HF. Several medications prescribed to patients with HF are aimed at
blocking neuroendocrine responses to normalize sodium balance and decrease fluid
retention (Hunt et al., 2009). Data from our recent study suggest that these drugs may not be
sufficiently effective in patients with advanced HF to prevent rehospitalization (Lennie et
al., 2011), making dietary sodium restriction necessary (J. Arcand et al., 2011). However,
most patients with HF state they do not know the best methods for limiting sodium in the
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diet (Chung, Lennie, Worral-Carter, Bentley, & Moser, 2004; Moser, Doering, & Chung,
2005) and need additional information from health care providers regarding how to follow a
low sodium diet (Bentley, De Jong, Moser, & Peden, 2005; Sheahan & Fields, 2008). This
information may be most effective if provided in the context of the patient’s typical eating
habits (Welsh et al., 2010). Providing individual patient teaching based on assessment of
patient’s usual dietary patterns in addition to written instructions has been demonstrated to
improve the ability to follow a low sodium diet (J. A. Arcand et al., 2005).
A2.2. Inflammation and omega-3 fatty acids
Inflammation: Heart failure is now conceptualized as a multi-system syndrome in which
systemic inflammation is a major pathologic process (Conraads et al., 2002).
Proinflammatory cytokines have pleotropic actions that directly or indirectly elicit many
pathologic pathways underlying HF including activation of neurohormones, catabolism of
body tissues, sodium and water retention, and impairment of ventricular function (Hedayat,
Mahmoudi, Rose, & Rezaei, 2010; Mann, 2004). Cytokines are also implicated in a group of
inflammation-induced symptoms collectively called sickness behaviors (Dantzer, 2009).
These sickness behaviors include malaise, fatigue, decreased socialization, and decreased
appetite. Thus, decreasing the proinflammatory cytokine response is an attractive target for
improving HF symptoms. Accordingly, three anti-TNFα clinical trials were conducted. Two
were trials of etanercept, a TNF inhibitor, and one was a trial of infliximab, an anti-TNF
antibody. Unfortunately, none of the trials showed any benefit; in fact treatment may have
increased mortality (Heymans et al., 2009). Both drugs are global blockers of TNFα
activity. Given that TNFα has immune-regulatory and other regulatory activities, low levels
of TNFα activity may be necessary for normal function (Dantzer, 2009). Interventions, such
as omega-3 fatty acid supplementation, that alter inflammatory pathways which stimulate
release of pathologic levels of TNFα provide a viable alternative.
Omega-3 fatty acids: Omega-6 and omega-3 are essential fatty acids, meaning they must be
derived from the diet. They play important roles in mediating cellular inflammatory
responses. Tissue injury or stress trigger metabolic pathways that convert these fatty acids
into the biologically active metabolites. Omega-6 fatty acids form arachodonic acid
metabolites such as prostaglandins PGE2, thromboxane TXA2, and leukotrienes LTB4 and
LTC4. These metabolites are potent mediators of inflammation and promote
vasoconstriction as well as platelet aggregation (Heller, Theilen, & Koch, 2003). In addition,
PGE2 plays a role in cytokine-induced sickness behavior by serving as a brain mediator for
effects of peripherally produced cytokines (Dantzer, 2009). In contrast, the omega-3 fatty
acids eicosahexaenoic acid (EPA) and docosahexaenoic acid (DHA) produce less
inflammatory metabolites such as PGE3, and PGI3, thrombaxane TXA3, and leukotrienes
LTB5 and LTC5. These metabolites suppress platelet aggregation, promote vasoconstriction,
and do not mediate cytokine-induced sickness behaviors. Omega-6 and omega-3 fatty acids
compete for the same enzymes during the process of forming their respective metabolites.
Consequently, tissues with higher amounts of omega-3 fatty acids produce less
inflammation than tissues with more omega-6 fatty acids (Heller et al., 2003). As shown in
Preliminary Data to Support the Intervention Section, most patients with HF are not likely to
achieve an adequate level of dietary EPA and DHA. The omega-3 index has been
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recommended as a way to quantify the proportion of omega-3 fatty acids in cell membranes
and can be used to determine adequacy of omega-3 fatty acid intake. It is defined as the
amount of EPA plus DHA in erythrocyte cell membranes expressed as a percentage of total
membrane fatty acids (Harris & Von Schacky, 2004). An omega-3 index of >4% is
associated with a significant decrease in risk of sudden cardiac death (Harris, 2008). Eight
weeks of supplementation with 1 g of EPA/DHA per day for 8 weeks results in an omega-3
index of 6.4% (Zhao et al., 2009).
A2.3. Oxidative stress and lycopene
Oxidative stress: Oxidative stress, defined as oxygen-free radical production that exceeds
cellular antioxidant capacity, is associated with hospital readmission for exacerbation of HF
symptoms (Rogowski, Shnizer, Wolff, Lewis, & Amir, 2011). Hypoxia resulting from
impaired cardiac output is proposed to increase the production of uric acid via stimulation of
the enzyme xanthine oxidase (Doehner & Anker, 2005). An important consequence of this
pathway is the production of free oxygen radicals. When production of free oxygen radicals
exceeds the antioxidant capacity of the cell, excess free oxygen radicals interact with
functional cellular metabolites including nitric oxide, which maintains vascular tone
(Doehner & Anker, 2005). Loss of nitric oxide increases vascular resistance further
impairing cardiac output and worsening HF symptoms (Doehner & Anker, 2005; Rogowski
et al., 2011). In this respect, uric acid can be used as a marker of oxidative stress (Anker et
al., 2003). Lipid peroxidation is another consequence of excess oxygen-free radicals. In this
pathway, free radicals remove electrons from polyunsaturated fatty acids in cell membranes
altering cell membrane function. Cellular damage from oxidative stress in turn can stimulate
inflammation (Anker et al., 2003). Plasma levels of malondialdehyde (MDA) and 8-iso-
PGF2a isoprostane are markers of lipid peroxidation (Polidori et al., 2002). Higher levels of
these oxidative stress markers have been associated with lower levels of antioxidants,
particularly lycopene, and more impaired cardiac output in patients with severe HF (Polidori
et al., 2002, 2004). This indicates the need to increase the anti-oxidant capacity of patients
with advanced HF. Providing additional dietary sources of anti-oxidants is a simple way to
improve antioxidant status.
Lycopene: Lycopene is among the most abundant of dietary carotenoids that function as
antioxidants (Pennathur et al., 2012; Shi & Le Maguer, 2000a,b; Young & Lowe, 2001). It is
considered one of the most potent antioxidants; capable of limiting cellular damage from
excess oxygen-free radical production (Basu & Imrhan, 2007). Levels of lycopene in the
body have been shown to increase with respect to the amount of lycopene in the diet (Basu
& Imrhan, 2007). This indicates that lycopene levels are sensitive to dietary intervention.
Approximately 80% of the lycopene consumed in the United States comes from processed
tomato products (Clinton, 1998). The best sources of dietary lycopene are tomato-based
pasta sauces, tomato soup, canned tomatoes, tomato sauce, tomato paste, and tomato or
tomato-based juices (Clinton, 1998). A wide range of dietary lycopene supplements (5.7–40
mg) have been tested with evidence of antioxidant effects at each level (Basu & Imrhan,
2007). Although supplements as low as 5.7 mg have demonstrated antioxidant effects, the
evidence was from healthy volunteers without oxidative stress. Higher levels are likely
needed for those with oxidative stress. However, the data suggest that dietary
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supplementation need not exceed 20–25 mg to be effective in reducing oxidative stress (A.
V. Rao, Ray, & Rao, 2006).
A3. Preliminary Data to Support the Intervention
A3.1. Data from BMI, nutrition, inflammation, and heart failure outcomes
R01NR009280; T. A. Lennie, PI—A total of 248 HF patients completed 4-day food
diaries. Because food intake has been shown to differ on weekends versus weekdays, food
diaries were recorded Sunday (Day 1) through Wednesday (Day 4). The food diaries were
reviewed by dietitians and analyzed with Nutrition Data Systems for Research software.
During the diary recording period, patients completed Memorial Symptom Assessment
Scale—Heart Failure for symptom measurement and Minnesota Living with HF
questionnaire for measurement of quality of life. To demonstrate the effects of symptoms on
quality of life, scores on Minnesota Living with HF are compared in Table 1 between
patients in whom the symptoms of edema, fatigue, or shortness were present versus absent
during the prior 7 days. Quality of life was worse in patients who reported edema (t262 = 5.6,
p < .001), fatigue (t261 = 10.6, p < .001), or shortness of air (t261 = 7.6, p < .001) was present
during the prior 7 days.
To demonstrate effectiveness of the proposed intervention on symptoms, patients were
dichotomized according to dietary sodium intake above and below 3 g; lycopene intake
above and below group median intake of 2,235 mg; omega-3 intake above and below group
median intake of 1.6 g. Patients were then grouped according to quality of diet: Worst diet =
sodium intake above 3 g and both lycopene and omega-3 intake below median. Best diet =
sodium intake below 3 g and both lycopene and omega-3 intake above the median. Poor diet
= having one component meeting best criteria. Table 2 shows a comparison of the frequency
of reported edema, fatigue, and shortness of air among the four diet quality groups. Good
diet = having two components meeting best criteria. Fewer patients in the Best diet group
reported having symptoms of fatigue (χ2 = 11, p = .01) and shortness of air (χ2 = 10, p = .
018). Given that quality of life was lower in patients with symptoms and that symptoms
were more common in patients with lower quality diets, we tested whether quality of life
was lower in patients with low quality diets. Table 3 shows a comparison of quality of life
scores among the four diet quality groups. Patients in the Worst diet group had significantly
poorer quality of life scores than patients in the Best diet group by one way ANOVA (F3,244
= 2.2, p < .02) with LSD post hoc tests.
It should be noted that the Best diet group contained the smallest number of patients
indicating that most patients did not spontaneously achieve the dietary levels of all three
nutrients that would be beneficial for decreasing symptoms and improving quality of life.
Combined these results provide evidence of both the need for and potential effectiveness of
our proposed nutrition intervention on symptoms and quality of life.
A3.2. Evidence for dietary sodium reduction component—The proposed dietary
sodium reduction component was pilot tested in a randomized, repeated measures clinical
trial by co-investigator Dr. Welsh (Welsh et al., 2012). Fifty-two patients with heart failure
were randomized to either the intervention group (n = 27) or usual care (n = 25) group. The
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mean daily sodium intake was not significantly different between the intervention (2,880 ±
1,489 mg) and usual care (3,070 ± 1,352 mg) groups at baseline (t47 = 0.46, p = .64).
Analysis of covariance with baseline sodium intake as a covariate revealed that dietary
sodium intake was significantly lower in the intervention group (2,262 ± 925 mg) than usual
care (3,164 ± 886 mg) at 6 months (p = .01).
A3.3. Evidence for lycopene supplementation component—The lycopene
component was pilot tested in a randomized, controlled clinical trial headed by co-
investigator Dr. Biddle (under review). Twenty-two patients with HF randomized to an
intervention of V-8 juice (11.5 oz/day; 25 mg lycopene) for 3 months were compared to a
usual care group of 18 patients. Four 24-hour diet recalls were obtained on random days
over a 3-week period to determine dietary lycopene intake and blood was drawn for
lycopene at baseline and 3 months. Serum lycopene levels were comparable between groups
at baseline. Levels increased markedly at 3 months in the intervention group but were
unchanged in the usual care group [statistics in original proposal were deleted here because
results are in review elsewhere (Biddle et al., in review)]. The intervention was easily
implemented, well tolerated by patients, and had a 100% adherence rate.
A3.4. Evidence for omega-3 supplementation component—We previously
demonstrated that higher dietary intake of omega-3 fatty acids is associated with lower
plasma levels of the inflammatory markers: soluble TNF receptors sTNF-R1 and sTNF-R2
(Lennie et al., 2005). Patients who consumed >1.2 g of omega-3 fatty acids had significantly
lower levels of sTNF-R1 than patients who consumed <1.2 g of omega-3 fatty acids (2,323
+ 1,034 vs. 3,307 ± 1,973 pg/ml; respectively). The same was true for sTNFR2 (4,114 ±
2,646 vs. 5,409 ± 2,801, respectively). The GISSI-HF trial provides strong evidence for the
safety, efficacy, and tolerability of the proposed omega-3 supplementation. Nearly 3,500
patients with HF were randomized to receive 1 g of omega-3 fatty acids/day for a median of
3 years (Tavazzi et al., 2008). Omega-3 supplementation was well tolerated and did not
produce adverse effects in patients with HF. The treatment resulted in a modest decrease in
all cause hospitalization and death. Support for the effectiveness of omega-3 fatty acid
supplementation in lowering inflammation is found in a placebo controlled study of 75
patients with HF (38 omega-3 vs. 37 placebo; Zhao et al., 2009). Omega-3 supplementation
of 300 mg EPA/DHA/day for 3 months resulted in a 25% reduction in plasma TNFα levels
in the omega-3 supplementation group compared with no change in the placebo group.
B. Innovation
Palliative care is indicated for patients with incurable conditions in which medical treatment
is no longer effective in managing symptoms. In these cases, complementary interventions
for symptom management that can be easily implemented by health care providers for
patients low physical reserve and limited financial resources are needed. The proposed study
is a test of a novel low cost intervention requiring minimal patient effort that is designed to
be carried out as part of routine home visits. It is the first combined intervention that targets
three nutrients which individually have been shown to affect pathologic pathways
underlying symptoms of HF. It will be the first study to control for dietary intake of other
nutrients that could alter or mask the effects of the intervention. This will also be the first
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study to measure whether the intervention achieves the desired changes levels of
inflammatory mediators, markers of oxidative stress, and body fluid.
C. Approach
C1. Design
The proposed randomized, placebo-controlled nutrition intervention study is a two-group,
prospective design (nutrition intervention vs. placebo) in which HF symptoms, health-
related quality of life, and serum levels of proinflammatory cytokines and markers of
oxidative stress are measured at baseline and Months 3 and 6 of the intervention. Patients
will be blind to group assignment however it is not possible to blind interventionists. Data
on HF symptoms and health-related quality of life will also be collected at 9 and 12 months
from baseline. Data on patient hospitalization and death (time to first event) will be collected
monthly for 12 months from baseline. Sociodemographic, clinical, and other variables that
can affect study outcomes will be collected at baseline and are: body weight, height,
medications, and depressive symptoms. The following biological markers of adherence to
the nutrition intervention will be collected at baseline, 3-, and 6-month time points:
erythrocyte omega-3 index, serum lycopene levels, and dietary sodium intake. The
following biological indicators of intervention effects on pathologic pathways underlying
symptoms will be collected at baseline, 3-, and 6-month time points: fluid status (body
weight), oxidative stress (malondialdehyde, uric acid, and 8-iso-PGF2a isoprostane), and
cytokine (TNFα, sTNF receptors, and IL-10) levels. The protocol is designed to minimize
subject burden by limiting the number of questionnaires to be completed and collecting data
in patient homes unless an alternative site is preferred.
Rationale for 2 group design—A typical approach to this type of study would be to use
a 4 or 5 group design in which each component of the intervention is tested separately and
compared to the combined intervention. However, each component of the intervention has
already been demonstrated to have beneficial effects. We are not hypothesizing that any one
component of the intervention is more effective than others, but rather that the combined
intervention is novel. Moreover, Figure 1 demonstrates the interactive nature of the
pathologic pathways underlying HF symptoms and illustrates the importance of providing an
intervention that concurrently targets all three pathways. Each of these pathways, if
untreated, could trigger responses that would diminish the effectiveness of an intervention
aimed at treating one of the other single pathways. Thus, any test of a single nutrition
component would require that we control or account in some way for the effects of the other
components. This is most effectively accomplished by providing the proposed combined
intervention.
Sample and setting—A total of 150 patients (75 per group) will be assigned to groups by
stratified (by gender) random assignment. Based on an estimated attrition of 25% derived
from previous studies, we have planned and budgeted for recruitment of 200 patients.
Attrition by mortality is an outcome so it does not reduce the sample. University of
Kentucky (UK) Chandler Medical Center will serve as the recruitment site. The UK
Chandler Medical Center is a regional tertiary care referral facility and is the largest
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academic medical center in Kentucky. In a recent study, our research team recruited 37 HF
patients (mean age 61 ± 15 years; 48% female, 84% Caucasian, 14% African-American, 2%
Hispanic) for a complex, longitudinal project in less than a month. Despite the fact that HF
is equally distributed between the genders, the representation of women in many studies of
HF has been poor. In order to represent women in this study we will enroll 50% women. The
population of HF patients at all UK Chandler Medical Center clinical sites is approximately
50% women so we do not anticipate problems in obtaining an adequate sample of women
for this study. This coupled with our experience in two studies (one of 90 [45% women;
22% African-American] HF patients and another in 135 patients [52% women; 28% African
American]) recruited from a HF service and from local community hospitals demonstrates
our ability to recruit women and minorities.
Inclusion/exclusion criteria—Patents recruited will have a diagnosis of chronic HF with
either preserved or non-preserved ejection fraction. This is the population enrolled in all of
our preliminary studies and interventions have been equally effective in both groups. The
diagnosis and etiology of chronic HF will be confirmed by a HF cardiologist using
established criteria (Hunt et al., 2009; Packer, Cohn, & on behalf of the Steering Committee
and Membership of the Advisory Council to Improve Outcomes Nationwide in Heart
Failure, 1999). Other inclusion criteria are: (a) have undergone evaluation of HF and
optimization of medical therapy, (b) NYHA functional classification of III or IV (advanced
HF), (c) have not been referred for heart transplantation, (d) able to read and speak English,
and (e) no cognitive impairment that precludes giving informed consent or ability to follow
protocol instructions. Patients will be excluded if they have: (a) BMI <17 or >45 kg/m2
(Fontaine, Redden, Wang, Westfall, & Allison, 2003; Wilson & Morley, 1999) (b) valvular
heart disease as the etiology of HF, (c) myocardial infarction within prior 3 months, (d)
uncontrolled diabetes mellitus (HgA1c > 8%), (e) co-existing illness known to be associated
with systemic inflammation, decreased appetite, fatigue, edema, or weight loss, or (f)
currently taking dietary supplements that contain lycopene or omega-3 fatty acids.
NYHA functional class will be determined by patient interview at the time of recruitment to
establish eligibility. Based on patients’ report of symptoms associated with performing their
usual activities, they are assigned a classification of I (ordinary physical activity causes no
symptoms of fatigue, dyspnea, angina, or palpitations), II (symptoms with ordinary physical
activity and slightly limited physical activity), III (symptoms occur with less than ordinary
physical activity and produce marked limitation of activity), or IV (symptoms occur at rest
and unable to carry on any physical activity without symptoms; Mills & Haught, 1996).
Reproducibility both among different raters (inter-rater reliability) and across the same rater
(intra-rater reliability) will be insured by training raters and testing them in sample patients
until agreement is 100%. We have extensive experience classifying patients with HF by
NYHA functional class having successfully enrolled and classified a combined total of more
than 1,200 patients in our previous studies.
Cognitive impairment: The Mini-Cog will be used to screen for cognitive impairment
(Borson, Scanlan, Watanabe, Tu, & Lessig, 2006). The instrument is a simple, easily
administered test composed of a three-word recall and clock drawing test (scored based on a
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combination of the number of words recalled and ability to correctly draw clock screens for
cognitive impairment). The instrument is a reliable, sensitive, and specific screening tool in
multiple patient populations, including outpatients (Borson et al., 2006) and minorities
(Borson, Scanlan, Chen, & Ganguli, 2003; Borson, Scanlan, Watanabe, Tu, & Lessig, 2005).
C2. Intervention
The intervention is designed to complement medical management. Therefore, both the
nutrition intervention and placebo groups will continue to be medically managed by their
health care provider as usual. Usual care includes advice to limit dietary sodium, but only
includes brief instruction that can be provided during routine clinic visits. Other nutrition
advice is not given. In order to avoid introducing the confound of extra attention paid to the
intervention group, the placebo group will have the same visit and call schedule as the
intervention group. Both groups will be visited at baseline, Months 3 and 6 for data
collection and intervention (Table 4). There is one additional intervention visit for both
groups 1–2 weeks after baseline and one intervention call 2 weeks after that visit. Both
groups will receive phone calls at Months 9 and 12 for data collection (Table 4). Finally,
both groups will receive phone calls to collect monthly hospitalization data and to identify
problems or questions.
We will employ interventionists who are unblinded to group and data collectors who are
blinded to group for the study. Interventionists are cardiovascular clinical nurse specialists
working with our team for several years who assisted in the development of the intervention,
who have delivered the intervention in other of our studies, and who have years of clinical
and research experience. Data collectors are trained and certified individuals working with
our research group who have years of data collection experience. Both interventionists and
data collectors will be trained, tested and have their training updated every 6 months by the
PI and co-investigators throughout the study to maintain intervention and protocol fidelity.
Dietary sodium reduction—The dietary sodium reduction component is our education
and skill building intervention used successfully (see preliminary studies) and is based on
the Theory of Planned Behavior (TPB; Welsh et al., 2010). The intervention addresses key
factors known to promote positive health behavior changes: patient attitude, subjective
norm, and perceived control (Welsh et al., 2010). The individualized theory-based teaching
will be structured according to each patient’s actual dietary habits using (J. A. Arcand et al.,
2005; Welsh et al., 2010) three random, 24-hour diet recalls. These data will be collected by
data collectors over the 2 weeks prior to baseline, Month 3, and 6 visits in both groups. A
summary nutrient analysis report that provides information on the amount of vitamins and
minerals in the diet in comparison to recommended levels will be generated for both groups.
The placebo group will receive information about their nutritional intake, including sodium,
but will be given only generic advice about sodium intake. For example, a patient with a
sodium intake of 2,500 mg/day would be advised to “keep up the good work,” while one
with an intake of 4,500 mg/day would be advised to “reduce salt intake.” Questions will be
answered generically, without using intervention specifics and strategies. The intervention
group will receive the same summary nutrient analysis plus an additional report listing all
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foods consumed ranked from highest to lowest in sodium content. This will be used to
identify the specific foods in diet contributing to high sodium intake and to allow the
intervention to be individualized.
Given the complexity of adherence behavior (Riegel et al., 2009) (also multiple studies
conducted by our team on this topic; Bentley et al., 2005; Chung et al., 2004, 2008; De Jong
et al., 2011; Lee, Moser, Lennie, & Riegel, 2010; Lee et al., 2009; Lennie, Moser, &
Habash, 2003; van der Wal, Jaarsma, Moser, van Gilst, & van Veldhuisen, 2007, 2010; van
der Wal et al., 2006; Wu, Moser, Chung, & Lennie, 2008a, 2008b; Wu et al., 2009; Wu,
Moser, Lennie et al., 2008) it is not likely that any one intervention will work for all
patients. Therefore, interventions need to be flexible enough to respond to individual needs
of patients as we do in our intervention. The self-management intervention is individualized
for each patient’s unique characteristics, starting with their eating behavior as above. Often,
patients do not recognize symptoms such as weight gain, difficulty breathing, and ankle
swelling as symptoms related to heart failure (Carlson, Riegel, & Moser, 2001). Patients
frequently believe they cannot control their symptoms (Carlson et al., 2001; Horowitz, Rein,
& Leventhal, 2004) or they believe dietary sodium has a minor effect on their symptoms
(Schiff, Fung, Speroff, & McNutt, 2003). Thus, we explain, at a level that the patient can
understand, the pathophysiology of HF and the cause of fluid retention. Symptoms of fluid
retention are listed. A clear connection is made between symptoms of fluid retention and
worsening HF. The impact of high sodium foods on fluid retention is emphasized. Negative
outcomes of fluid retention such as increased swelling, shortness of breath, weight gain, and
rehospitalizations are then emphasized. Visual aids are provided for the entire intervention.
The patient is then informed they can make a difference in their symptoms and outcomes by
eating a low sodium diet. Positive outcomes of adherence to a low sodium diet are
described: decreased swelling, decreased shortness of breath, decreased hospitalizations, and
more energy. This information is vital in creating a positive attitude toward dietary sodium
adherence. According to the TPB, this will assist the patient in forming strong beliefs that
mostly positively valued outcomes will result from adhering to a low sodium diet. Signs and
symptoms of fluid retention are reviewed, and patients are taught how and asked to weigh
themselves daily. In order to assist the patient to develop a strong subjective norm, the value
of the low sodium diet in managing HF to the patient’s providers is instilled.
Perceived behavioral control is addressed by providing patients with the necessary resources
to overcome impediments to following a low sodium diet. Perceived power will be increased
by assisting the patient to realize he/she has multiple resources to facilitate the behavior and
few barriers to impede the behavior. This includes barriers specifically identified in baseline
questionnaires as well as barriers we identified: lack of knowledge, interference with
socialization, and lack of food selections (Bentley et al., 2005). All teaching related to a low
sodium diet will be individualized. For example, when discussing high sodium foods to
avoid, specific high sodium foods found on the patient’s diet recall are identified. Low
sodium alternatives are discussed. Visual aides are provided for some food comparisons. For
example, test tubes of sodium are compared for potato chips versus a medium potato and 3
ounces of ham versus 3 ounces of pork chop. Additional test-tubes are also used for patient
demonstration. Patients are taught to read food labels, using food labels specific to foods
listed on the 3-day food diary. The patient’s food recall is used to plan a sample menu.
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Alternatives to high sodium foods are mutually agreed upon based on the patient’s food
preferences. Living arrangements and the patient’s ability to cook or buy groceries are
assessed with each patient. In addition, many HF patients, due to other comorbidities such as
diabetes, have more than one dietary guideline to follow. This potential obstacle is also
addressed for each patient. Salt substitutes are discussed and specific, written ideas for herb
or spice blends are given to the patients. Written low sodium recipes are also provided to the
patient.
Eating out is also an obstacle to a low sodium diet adherence. The patient’s favorite
restaurants are identified. A booklet, Nutrition in the Fast Lane, is given to the patient. This
booklet contains sodium and other nutrient information. The patient is asked to describe
what they typically order at a specific restaurant. The sodium content is looked up in the
booklet and lower sodium alternatives are identified.
Lycopene supplementation—The primary source of lycopene supplementation for the
intervention group will be a tomato-based juice (either low sodium tomato or V8 juice).
Patients will be provided with a supply of their preferred juice at each visit and instructed to
consume juice daily with breakfast or other preferred time. To provide variety, they will be
given a list of other food products containing 20–25 mg of lycopene that can be substituted
(Table 5). The placebo group will be provided with their choice of juices listed in Table 5 at
each visit. At each visit, the interventionist will discuss any difficulties with taking
supplements and problem solve if needed to enhance adherence. Based on plasma lycopene
levels, adherence to the intervention was high and maintained throughout our preliminary
study and control patients did not spontaneously consume higher levels of lycopene.
Omega 3 supplementation—At baseline and 3 months, patients will be provided with 3
months supplies of omega-3 fatty acid capsules (OmegaBrite; 350 mg EPA, 50 mg DHA/
capsule) or placebo (rice bran oil 500 mg/capsule) depending on group assignment. They
will be instructed to take three capsules per day, one with each meal. At each visit, the
interventionist will problem solve if needed with patient to enhance adherence.
Baseline visit—The interventionist and data collector will visit patients in their homes.
Data on socio-demographics, clinical characteristics, medications, depressive symptoms,
quality of life, symptom burden, height, and weight will be collected at beginning of visit
and blood will be drawn by the data collector who will leave. The interventionist will then
provide all patients with a digital body weight scale, instruction on weighing daily, and ask
them to do a return demonstration. Patients will also be given instructions regarding all
aspects of the nutrition intervention/placebo.
Visit 2
Nutrition intervention group: The interventionist will make a second home visit
approximately 1–2 weeks after baseline to both groups. The interventionist will review
information previously presented and in both groups will determine any problems to
following any of the three components of the intervention.
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Follow-up phone call
Placebo group: Follow-up phone call will occur within 2 weeks of Visit 2. The
interventionist will inquire about general welfare, ask whether the patient is having
difficulties with the taking capsules or juice, and answer any questions.
Nutrition intervention group: Follow-up phone call for the intervention group will occur
within 2 weeks of Visit 2. The interventionist will reinforce previously taught information,
review success in meeting goals, help patients problem solve any new barriers, and applaud
positive changes made in the diet, and discuss problems or concerns related to capsules or
juice intake.
Month 3 and month 6 visits—The interventionist and data collector will visit patients in
their homes. The data collector will obtain all appropriate data and then leave.
Placebo group: The research nurse will review the summary nutrient analysis report
generated from the three 24-hour food recalls collected in the 2 weeks prior to the visit and
answer all questions.
Nutrition intervention group—Prior teaching will be reviewed and reinforced. The
research nurse will review the summary nutrient analysis report and the list of foods ranked
by sodium content generated from the three 24-hour food recalls collected in the 2 weeks
prior to visit. The nurse and patient will jointly identify low sodium alternatives for foods
high in sodium. Goals and strategies for substituting high sodium foods with low sodium
alternatives will be jointly developed. The interventionist will help the patient problem solve
ways to overcome any new barriers identified and discuss any problems or concerns related
to capsules or juice intake.
C3. Procedure
Permission for this study will be obtained from the University of Kentucky Institutional
Review Board. Patients will be referred to this project by physicians or nurse practitioners in
the Chandler Medical Center clinics who will obtain permission from patients for nurse
recruiter to contact. Trained nurse research assistants will confirm eligibility and screen for
cognitive impairment. Those identified as impaired will be informed they do not meet study
eligibility. For eligible patients, study requirements will be explained and if patient agrees to
participate, signed informed consent will be obtained. The patient will then be randomly
assigned to either the nutrition intervention or placebo group using a randomization table
stratified by gender. The baseline visit by the interventionist and data collector will be
scheduled. Over the 2 weeks prior to the baseline, 3-, and 6-month visits a data collector will
call on 3 days (2 random weekdays and 1 random weekend day) to obtain 24-hour diet
recalls and generate nutrient analysis reports. The interventionist will make baseline, follow-
up phone call, 3-, and 6-month visits as described in the intervention.
Blood will be drawn at the baseline, Months 3 and 6 visits. Blood will be placed on ice and
transported to the Biochemical Analysis Laboratory of the UK CR-DOC to be spun down
and plasma or serum, depending on analyte, allocated into tubes and stored at −70 until
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analyzed. Red blood cells for fatty acid analysis will also be frozen and stored. Samples to
be sent to our collaborator’s laboratory will be shipped overnight by the UK CR-DOC on
dry ice according to International Air Transportation Association Training Packing
Instruction 650 for Diagnostic Specimens. In Years 2 and 3, when volume of visits is high,
we will have two data collectors for blood draws at the 6-month time point.
Data on socio-demographic, clinical characteristics, medications, depressive symptoms,
quality of life, and symptom burden will be collected in person at baseline. Data on
medication changes, quality of life, and symptom burden will be collected in person at 3-
and 6-month visits. Hospitalization and mortality data will be collected monthly for 12
months to obtain patient outcomes. The data collectors will review medical records and call
patients or family members monthly to obtain information about hospitalization and
mortality. Data on quality of life and symptom burden at 9 and 12 months will be collected
by telephone during the corresponding monthly phone call to collect hospitalization data.
Patients will be compensated $25 for their time at the baseline, Months 3 and 6 visits, and at
the final 12-month phone call.
C4. Measurement of Variables
Rationale for timing of variable measurement—Baseline measurement provides
indicators of the success of randomization and control values for between-group
comparisons at other time points. Measurement at the 3-month time point provides
indicators of intermediate effects of the intervention while the 6-month time point provides
indicators of long-term adherence and insights into the biological mechanisms underlying
hypothesized changes in symptoms and quality of life. The primary interest in measurement
at the 9- and 12-month time points is to determine long-term effects on the primary study
outcomes of symptom burden, quality of life, and hospitalization or death. While it would be
of interest to also measure biological markers at the 9- and 12-month time points this would
require two visits for blood draws increasing subject burden. Given that the mechanistic
components of the intervention will be demonstrated by measurement of biological markers
at the baseline, 3, and 6 months, we do not believe the added subject burden or cost merits
the limited additional information that would be gained by requiring visits for blood draws
at 9 and 12 months.
Specific Aim 1—To determine the effects of a 6-month nutrition intervention on symptom
severity, health-related qualtiy of life, and HF rehospitalization or all-cause death at 3-, 6-,
9- and 12-month time points.
Symptom burden: Physical symptom burden will measured using items from the Memorial
Symptom Assessment Scale—Heart Failure (MSAS-HF) (Zambroski et al., 2005). The
MSAS-HF is a 32-item questionnaire adapted from Portenoy’s Memorial Symptom
Assessment Scale that is designed to provide multidimensional information about symptoms
experienced by patients with HF. Patients will be first asked if the symptom was present
during the previous 7 days. If present, three characteristics of each symptom will be rated:
frequency of symptom, severity of symptom, and degree symptom of distress. Frequency is
rated on a scale from 1 to 4 (rarely to almost constantly), severity rated on a scale from 1 to
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4 (mild to very severe) and distress rated on a scale from 0 to 4 (not at all to very severe).
Burden score for each symptom can range from 0 (no burden) to 12 (greatest symptom
frequency, severity, and distress). For the purposes of testing Hypothesis 1a, incidence and
burden score for three symptoms (shortness of air, edema, and lack of energy) will be
compared between groups. The combined total symptom burden score (shortness of air +
edema + lack of energy) will also be compared. The full instrument has three subscales that
measure psychological, physical, and HF-specific symptoms. Subscales have reported
reliability estimates of 0.92, 0.83, 0.87, and 0.73, respectively, in a similar patient
population (Zambroski et al., 2005).Total symptom subscale scores will be used in future
secondary analyses to explore the effect of the intervention on total symptom burden.
Quality of life: Quality of life will be measured using a disease-specific instrument, the
Minnesota Living with Heart Failure Questionnaire (LHFQ; Rector & Cohn, 1992a; Rector,
Johnson, et al., 1993; Rector, Kubo, & Cohn, 1987, 1993; Rector et al., 1995). The
instrument measures patients’ perception of how much their HF and its treatment affects
their ability to live as they want, and since its development it has been widely used in
research and clinical practice. It consists of 21 questions rated on a scale from 0 (no effect)
to 5 (very much). Item ratings are summed for a total score that can range from 0 to 105.
Higher scores reflect worse QOL. Questions concern a variety of physical and psychological
aspects of living with HF and include activities of daily living, economic issues, ability to
work, enjoyment of leisure time activities, relations with family and friends, sexual activity,
side effects from medications, depression, and impact of HF symptoms. The LHFQ is the
most commonly used disease-specific instrument used in HF research and is an appealing
instrument because it is inexpensive, short, easily understood by ill and elderly individuals,
self-administered, and easy to score.
Several investigators have examined the psychometric properties of the LHFQ in patients
with HF and found strong internal consistency reliabilities of the total, physical, and
emotional scales (Cronbach’s alphas ranging from .88 to .93; Bennett et al., 2002; Heo,
Moser, Riegel, Hall, & Christman, 2005; Rector & Cohn, 1992b; Rector et al., 1987; Riegel
et al., 2002). Support for the construct validity of the LHFQ has been reported in several
studies (Gorkin et al., 1993; Middel et al., 2001; Quittan et al., 2001). The LHFQ
discriminates among NYHA functional class groups (Bennett et al., 2002). The LHFQ was
more responsive to clinically important changes than the MOS SF-12 (Bennett et al., 2003).
The LHFQ was used in our study that demonstrated a relationship between HRQOL and
rehospitalization or mortality (Moser et al., 2009).
Hospitalization and mortality outcomes: HF rehospitalization and all-cause mortality will
be considered to have relative equivalence for two reasons. First, hospitalization is not a
routine component of care under current HF management guidelines (Hunt et al., 2009).
Patients are typically not hospitalized unless they develop an exacerbation that would be
life-threatening if not admitted for treatment. Second, the combined endpoint of HF
rehospitalization and all-cause mortality is useful, even preferred, when study variables
affect multiple end-points (DeMets & Califf, 2002). HF rehospitalization will be determined
by use of a combination of three methods we use previously in order to capture all
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hospitalizations and confirm correct classification of hospitalization (Lennie et al., 2011;
Moser et al., 2010; Wu et al., 2008a).
Hospital administrative records: UK Medical Center uses an integrated data delivery
system to track all patient encounters and document each patient contact with the healthcare
system within the medical center. Thus, comprehensive data are available on dates, times
and reasons for all hospitalizations.
Medical record review: We will corroborate the data from administrative records by
performing medical record review of each encounter noted in the system or reported to be
outside the system. An advanced practice nurse with clinical expertise in the management of
patients with HF blinded to group assignment will review hospitalizations to ensure accurate
categorization of reason. The nurse will be specifically trained to collect these data. The
diagnosis of HF exacerbation will be confirmed according to established criteria
(Hershberger et al., 2001; Krumholz et al., 2002).
Patient/family interview: There is always the possibility that a patient will be admitted to a
different hospital. Therefore, patients/families will be interviewed monthly to obtain self-
reports of admissions that can be used to trigger search for supporting administrative data
and medical record review data. Research associates will be trained to carefully interview
patients to identify all admissions. Patients will be asked to keep a diary of all hospital
admissions to reinforce their memory for these events (Hershberger et al., 2001). For
hospital admissions outside the system, discharge reports released to the patient will be
reviewed.
All-cause mortality will be determined by a combination of medical record review,
discussion with patients’ health care providers and family, automated hospital records and
review of county death records to obtain date and cause of death. At enrollment, patients
will be asked for contact information for a close friend or next of kin to be used if they are
unable to be contacted. If neither the patient nor these contacts can be located during follow-
up or if additional information is needed, the county death records will be searched. We used
these methods successfully to accurately categorize deaths (Lennie et al., 2011; Moser,
Stevenson, Woo, & Stevenson, 1994; Wu et al., 2009).
Specific Aim 2—To compare dietary sodium intake, markers of oxidative stress, and
proinflammatory/anti-inflammatory cytokine levels of patients in the nutrition intervention
group with patients in the placebo group at 3-and 6-month time points.
Dietary sodium intake: Twenty-four hour diet recall interviews will be used estimate
sodium intake and to identify high sodium foods and eating patterns for the sodium
reduction component of the intervention. Patients will be called on two randomly selected
weekdays and 1 weekend day during 2 weeks prior to baseline visit, Weeks 10 and 11 of
intervention (prior to Month 3 time point visit), and Weeks 34 and 35 of intervention (prior
to Month 6 time point visit). The interviews will be conducted by trained research assistants
under the supervision of Dr. Thomas. The diets will be analyzed using Nutrition Data
Systems-R (NDS-R) software (NCC, University of Minnesota) which is designed to obtain
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reliable food intake data via interviews. The NDS-R is a sophisticated diet analysis program
that is among the most complete and accurate diet analysis systems available. The software
has the capacity to provide output for over 102 nutrients and nutrient ratios. The database
contains nutrient content for more than 19,000 foods including over 160,000 variants in food
preparation method and ingredients. The database also contains nutrient information for diet
supplements and over 7,800 brand name and ethnic foods. The database contains dietary
supplements and medications containing sodium. Finally, the software allows direct input of
recipes for homemade foods.
Oxidative stress markers: These markers will be measured in the laboratories of Dr.
Brucker. Because it is difficult to measure reactive oxygen species directly in humans,
indirect markers of oxidative stress will used. Elevated levels of malondialdehyde and 8-iso-
PGF2a isoprostane will serve as markers of increased lipid peroxidation due to oxygen-free
radical production exceeding antioxidant capacity. Levels of these biomarkers are expected
to decrease in response to the lycopene component of the intervention (Polidori et al., 2002,
2004). Elevated levels of uric acid indicate increased production of oxygen-free radicals due
to increased xanthane oxidase activity. Because oxygen-free radicals are produced
downstream as a consequence of uric acid formation, uric acid levels will be used to indicate
presence of oxidative stress (Doehner & Anker, 2005). We expect patients with high uric
acid levels receiving the intervention to have lower levels of malondialdehyde and 8-iso-
PGF2a isoprostane than patients with high uric acid levels receiving the placebo. Venous
blood will be drawn into vacutainers containing trisodium citrate, EDTA and/or BHT
depending on the analysis, centrifuged in a refrigerated centrifuge and plasma separated and
allotted to micro-tubes and kept at −70°C prior to analysis.
Malondialdehyde: Lipid peroxidation, mainly malondialdehyde, will be measured
fluorometrically as thiobarbituric acid-reactive substances (TBARS) according to the
modified method using a Gilford Fluoro IV spectrofluorometer (Gilford Instrument, Oberlin,
OH) with excitation at 515 nm and emission at 550 nm after isobutyl alcohol extraction.
1,1,3,3-Tetraethoxypropane will be used as the standard (Ibrahim et al., 1997).
8-iso-PGF2a isoprostane will be measured in plasma using Enzo Life Sciences direct
ELISA kits. Sample concentrations will be determined by measuring optical density in a
microplate reader and calculated from a standard curve using a 4-parameter curve fit.
Uric acid will be measured using the colorimetric method at 590 nm as described in the
QuantiChrom Uric Acid Assay Kit by BioAssay Systems. For all assays, samples and
standards will be run in duplicate and inter- and intra-assay CV determined to assure
accuracy and reproducibility.
Pro- and anti-inflammatory cytokines: Serum levels of TNFα, soluble TNF receptors:
sTNFR1 and sTNFR2 will be measured as markers of proinflammatory cytokine activity
(Kell et al., 2002; Rauchhaus et al., 2000). Because the effects of proinflammatory cytokine
activity are moderated by anti-inflammatory cytokines, interleukin-10 (IL-10) will be
measured as a marker of anti-inflammatory cytokine activity. IL-10 has potent anti-
inflammatory properties including down regulation of TNFα, IL-1, and IL-6 production
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(Asadullah, Sterry, & Volk, 2003). IL-10 is higher in patients with HF than similarly aged
controls (Yamaoka, Yamaguchi, Okuyama, & Tomoike, 1999). Unfortunately, these higher
levels of IL-10 likely did not convey protection from inflammation as the ratio of IL-10 to
TNFα was lower in patients with HF. This suggests that despite having higher IL-10 levels,
proinflammatory cytokine activity was actually greater in patients with HF. Consistent
results have been reported in which the lowest ratio of IL-10 to TNFα was found in the most
symptomatic patients (Aukrust et al., 1999; Stumpf, Lehner, Yilmaz, Daniel, & Garlichs,
2003). Low IL-10 levels also may be related to cardiovascular events. These data indicate
that examination of the relationship between proinflammatory and anti-inflammatory
cytokines is necessary to obtain a full understanding of the role of inflammation in HF
symptoms. Cytokines and receptors will be measured using commercially available ELISA
kits (BioSource) by the Biochemical Analysis Laboratory of the University of Kentucky
Center for Clinical and Translational Science. Sample concentrations will be determined by
measuring optical density in a microplate reader and calculated from a standard curve using
a 4-parameter curve fit. Samples and standards will be run in duplicate and inter- and intra-
assay CV determined to assure accuracy and reproducibility. Samples in which the CV
exceeds 10% will be rerun.
Specific Aim 3—To compare three markers of intervention adherence, body weight,
plasma lycopene, and erythrocyte omega-3 index at 3- and 6-month time points between
intervention and placebo group.
Body weight: Patients will be provided with a high capacity (400 lbs) digital bathroom scale
with a large display screen for easy reading (Eatsmart Precision Plus, Wyckoff, NJ). They
will be instructed to weigh themselves at the same time each morning in light clothing after
voiding. The research nurse will verify the ability of patients to accurately obtain body
weight by having patients do a return demonstration during a home visit. Body weights will
be obtained on each day of the 24-hour diet recall and home visits.
Plasma lycopene levels: Plasma lycopene will be measured in the laboratory of Dr.
Schwartz at The Ohio State University. Venous blood drawn into EDTA vacutainer tubes
(Fisher Scientific, Pittsburg, PA) will be centrifuging at 1,000g at 4°C for 10 minutes and
plasma extracted.
Lycopene extraction: Plasma (0.5 ml) is mixed with 0.5 ml ethanol containing 0.1%
butylated hydroxytoluene and 2 ml of HEAT (10 hexane/6 ethanol/7 acetone/7 toluene). The
mixture is vortexed and centrifuged for 5 minutes at 300g. The upper non-polar layer is
removed and the remaining aqueous plasma mixture extracted twice more. The three non-
polar extracts are combined and dried under nitrogen. The dried extract is stored at −80°C
until HPLC-PDA analysis.
Lycopene HPLC-PDA (photodiode array) analysis: Samples will be reconstituted in 1:1
200 μl methanol/Methyl tert-butyl ether (MTBE) and filtered through a nylon syringe filter.
Samples will be placed into the HPLC system (Waters 996) interfaced with a PDA detector
(Waters 2996). Separation will be achieved using a YMC C-30 column (Waters Corp.,
Milford, MA). A 30-minute gradient method employing methanol and MTBE will be used
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with a flow rate of 1.3 ml/minute, column temperature = 30°C, and injection volume = 20 μl.
Lycopene will be quantified using an external calibration curve.
Omega-3 index: Omega-3 index will be defined as the ratio of EPA plus DHA as a
percentage of total fatty acids in the cell membrane of erythrocytes (Harris, 2008).
Erythrocyte membrane fatty acid analysis will be conducted in the laboratories of Dr.
Bruckner. Venous blood will be drawn into vacutainers containing EDTA and BHT,
centrifuged in a refrigerated centrifuge and the packed RBC separated allotted to micro-
tubes and kept at −70°C prior to analysis. All RBC samples will be spiked with 15:0 as an
internal standard. Samples will then be homogenized, and lipids extracted using
hexane:isopropanol (3:2 [v:v]) containing 0.05% butylated hydroxy-toluene. Total lipids
will be transmethylated using 14% boron trifluoride-methanol. Methylated samples, after
concentrating under nitrogen gas flow, will be injected into a gas chromatograph equipped
with a flame ionization detector and an Omegawax™ Capillary GC Column (length, 30 m;
inside diameter, 0.3–0 × 0.25 mm). Nitrogen flow will be maintained at between 1 and 10
ml/minute by use of an electronic pressure control. Temperature program for the column
will be with an initial temperature of 140°C increased at a rate of 20°C/minute up to 280°C
and held for 5 minutes. Peaks will be identified using fatty acid standards run with each
batch of samples (Szabo, Ibrahim, Sunvold, & Bruckner, 2003).
Measurement of other variables of interest: To completely characterize patients and
obtain data on potential intervening variables, information concerning the following
variables will be collected: age, sex, race/ethnicity, marital status and whether the patient
lives alone, education level, time since diagnosis, medication regimen, co-morbidity, and
body mass index. Data on age, sex, race/ethnicity, marital status, whether patient lives alone,
and education level will be collected by patient interview. Prescribed medication regimen
(i.e., drugs, doses, frequencies) will be obtained from patient interview and medical record
review to confirm patient report. Time since diagnosis will be determined by patient
interview and medical record review to document diagnosis of HF. The conversion of
asymptomatic ventricular dysfunction to overt HF usually is heralded by the occurrence of
activity intolerance as a result of one or both of the most common, dyspnea or fatigue. Thus,
length of time since diagnosis is the most commonly used indicator of duration of HF.
Co-morbidity will be measured at enrollment using the Charlson Index, interview format
(Katz, Chang, Sangha, Fossel, & Bates, 1996). Scores can range from 0 to 34 but because
each subject has HF they will have a score ≥1. Responses are summed, weighted, and
indexed into one of three categories (low, moderate, or high) according to the published
method. Reliability and validity have been demonstrated; specifically with regard to validity,
predictive validity was demonstrated when comorbidity category predicted mortality,
complications, health care resource use, length of hospital stay, discharge disposition, and
cost (Charlson, Pompei, Ales, & MacKenzie, 1987; Katz et al., 1996).
Body mass index (BMI) is recognized to be related to both HF symptoms and paradoxically
to longer event-free survival (Curtis et al., 2005; Horwich et al., 2001; Hunt et al., 2009).
BMI will be defined as body weight measured to the nearest 100 g divided by height
measured to the nearest meter square. Measurements by experienced research staff will be
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taken on patients without shoes and in light clothing using a digital scale and a portable,
professional grade stadiometer (Heyward & Wangner, 2004).
Emotional distress is common in patients with HF and associated with symptom burden
(Jurgens et al., 2009). Depressive symptoms will be measured using the Beck Depression
Inventory II (BDI-II). The BDI-II is an updated and revised version of the Beck Depression
Inventory that consists of 21 items (Arnau, Meagher, Norris, & Bramson, 2001; Steer, Ball,
Ranieri, & Beck, 1999; Steer, Clark, Beck, & Ranieri, 1999). Each item is rated on a 4-point
scale ranging from 0 to 3. Item ratings are summed and total scores can range from 0 to 63;
higher scores indicate a greater level of depressive symptoms. A person with a total score of
14–19 is considered to have mild depressive symptoms; total scores of 20–28 indicate
moderate depressive symptoms, total scores from 29 to 63 reflect severe depressive
symptoms (Beck, Brown, & Steer, 1996). Use of the BDI-II in previous cardiac studies has
demonstrated that the instrument is a sensitive depressive symptom screening tool (Ariyo et
al., 2000; Beck, Epstein, Brown, & Steer, 1988; Bush et al., 2001; Jiang et al., 2001; Lane,
Carroll, Ring, Beevers, & Lip, 2001). Previous investigators have demonstrated the
reliability and validity of the BDI in patients with CAD and HF (Ahern et al., 1990; Beck et
al., 1988; Bush et al., 2001; Carney et al., 2000, 2001; Frasure-Smith, Lesperance, &
Talajic, 1995; Jiang et al., 2001; Lane et al., 2001; Lesperance, Frasure-Smith, Talajic, &
Bourassa, 2002; Stein et al., 2000).
C5. Data Analysis and Power Considerations
Analyses—Data analysis will begin with a descriptive examination of the variables
including frequency distributions, means and standard deviations, medians, and interquartile
ranges, as appropriate to the level of measurement. Baseline comparisons of demographic/
personal and outcome variables between those who dropped out and those who completed
all waves of data collection will be determined using two-sample t-tests or chi-square tests,
and the rate of retention will be compared between the two treatment arms using the chi-
square test of association to test for differential drop-out. To control the overall Type I error
rate, the significance level for inferential statistical tests will be Bonferroni-corrected. It is
anticipated that the alpha level used to investigate the three study aims will typically be .01.
The focus of each of the aims is to test for group differences between the intervention and
placebo groups over time, with all four time points included in the Specific Aim 1 and the 3-
and 6-month time points included in the Specific Aims 2 and 3. For continuous outcomes,
these comparisons over time will be accomplished using repeated measures analysis of
variance with Fisher’s least significant difference procedure used for post hoc comparisons.
For time to hospitalization, survival analysis with the logrank test will be used to determine
an overall group difference, while Cox regression will compare the groups, adjusting for
demographic and relevant clinic covariates.
Power—For the repeated measures ANOVA models, with an alpha level of .01, a medium
effect size, 75 in each group, and a modest correlation among observations over time from
the same individual, the ANOVA F tests will have at least 85% power to detect differences
between groups, differences over time, or a group by time interaction. A medium effect size
in this context is defined as a difference such that the ratio of the standard deviation of the
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means to the standard deviation of the observations within the populations is as small as
0.25 (Cohen, 1988). Results provided in Section A3.1 suggest that effect sizes for
differences in QOL between those with and without at least one of the three major
symptoms are large, so the assumption of at least a medium effect size is likely to be
conservative. With 75 subjects per group and an alpha level of .01, the power of the logrank
test to detect a group difference in time to rehospitalization will be approximately 80% if the
hazard ratio for the comparison is as small as 2. One way to obtain a hazard ratio of this
magnitude would be if the rehospitalization percentages are 20% and 45% in the
intervention and placebo groups, respectively. While it is not possible to estimate the power
of Cox regression, it has been established that Cox regression is at least as powerful as the
corresponding logrank test (Schoenfeld, 1983). Power estimates were obtained using nQuery
Advisor (Elashof, 2005).
Figure 2 presents the timeline for the study.
C6. Potential Problems
Dietary sources of additional carotenoids and other antioxidants such as vitamins E and A
(Polidori et al., 2002), as well as omega-3 fatty acids could alter or mask the effects of the
intervention. Given that the intent of this study is to test an intervention that can be
implemented in community dwelling patients receiving palliative care, participants will be
instructed to consume their normal diet plus supplements. Consequently total carotenoid and
omega-3 intake from 3-day 24-hour recalls and supplements will be used in the analyses.
The 24-hour recalls will also be used to estimate intake of additional antioxidants which will
be controlled for in the analyses. Poor adherence is also a potential problem. We will have
measures of serum lycopene and erythrocyte fatty acid composition that will allow us
analyze data with respect to actual levels of these nutrients in the body rather than rely only
on self-report of adherence.
C7. Potentially Hazardous Procedures/Situations/Materials
The primary risk of hazardous exposure is to blood from venipuncture. Universal
precautions will be used to minimize possible exposure to blood.
Summary Statement Excerpts SRG Action: Impact/Priority Score: 27
Resume and Summary of Discussion
This application from University of Kentucky, submitted in response to RFA-NR-11-006
focuses on an important aspect of advanced heart failure therapy using nutritional and
behavioral approach. This intervention is likely to translate into self care of the patients and
improve the overall well being and outcomes. Precisely, the investigative team embarks on
improving advanced heart failure (HF) symptoms and quality of life in patients through a
low cost, easily administered intervention of dietary sodium restriction coupled with
lycopene and omega-3 fatty acid supplementation. The study topic is important and timely
since the outcome of the proposed aims if successful, are likely to significantly advance the
scientific knowledge and clinical intervention of advanced heart failure. The review group
has expressed following merits that include theory-based intervention guided and informed
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by prior work; strong team and excellent environment; expertise in RCT; feasible and easily
administered protocol; low cost, easily administered home-based, nutrition intervention is
considered innovative; approach is well articulated. However on the other hand, the review
group stated following weaknesses the include (1) respondent burden is a concern; (2) too
wide an age range (18–90); (3) unclear how optimization of medical therapy and evaluation
of heart failure are operationalized; (4) unclear if the omega 3 levels influence QOL; (5)
generalizability from one site; (6) better link needed between eating and suffering in
advanced HF as eating is a coping strategy; (7) focuses only on physiology- no psychosocial
outcomes. Overall the panel has expressed high level of enthusiasm (with correctable minor
weaknesses) based on high feasibility and home-based nutritional intervention that can be
easily administered and affordable and is highly likely to move the field of advanced heart
failure therapy forward.
Critique 1
Significance: 2
Investigator(s): 1
Innovation: 2
Approach: 2
Environment: 1
Overall impact—This application is highly responsive to the FOA and, as such, addresses
an important and timely topic of national significance. The proposed study is guided and
informed by prior conceptual and methodological work conducted by the multidisciplinary
team of investigators. The assembled team has research and clinical experience and
expertise with symptom management, nutritional interventions and those designed to
improve overall quality of life in advanced HF. The research environment(s) are particularly
well-suited to fulfillment of the major study aims. Collective past contributions to this area
of inquiry including those relevant to the integrated, theory-based proposed intervention add
to the likelihood of realizing study aims. If hypotheses are supported, the results of this
study have potential to improve symptoms and quality of life in individuals with advanced
HF in a low-cost and feasible (easily-administered) manner. Given the data to be collected,
the longitudinal nature/design of the RCT, and the patient population, some concern for
respondent burden exists.
Critique 2
Significance: 3
Investigator(s): 2
Innovation: 3
Approach: 3
Environment: 2
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Overall impact—This project address an important aspect of heart failure therapy:
nutrition using a well defined behavioral approach and instrumented by an experienced and
solid team of investigators. The intervention is simple, and if the behavioral aspect of self
management is learned by the patients, the benefit of this intervention (goal setting,
empowerment) may translate to other aspects of the self care of the patients and improve the
overall well being and outcomes. The enthusiasm of this reviewer is ameliorated by the
following aspects: the preliminary data only modestly support the expected changes in
clinical outcomes, the focus on just the nutrition may lack the comprehensive nature of
palliative care (so needed in this population), the strength of the approach to achieve such a
complex behavior (eating in the context of a suffering patient), accrual from just one center.
Critique 3
Significance: 3
Investigator(s): 1
Innovation: 3
Approach: 3
Environment: 1
Overall impact—[reiteration of aims deleted] Strengths include a double blind placebo
controlled study design, ample experience with similar studies, and a low cost intervention.
Significant weaknesses include an application devoid of a palliative care framework, lack of
palliative care expertise, lack of clinical correlation of the numerous physiologic markers in
the context of end of life, and an application replete with grammatical errors and
inconsistencies.
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FIGURE 1.
Conceptual framework: The proposed intervention targets three major pathways underlying HF symptoms: fluid overload
(depicted by small dashed lines), oxidative stress (dotted lines), and inflammation (large dashed lines). The symptoms produced
by these pathways (solid lines) are primary reasons for HF hospitalizations and decreased quality of life (Heo et al., 2007; Hunt
et al., 2009).
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FIGURE 2.
Estimated timeline for major activities in proposed study.
Lennie et al. Page 34
Res Nurs Health. Author manuscript; available in PMC 2014 May 06.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Lennie et al. Page 35
Table 1
Quality of Life Scores by Symptom Presence (Higher Score = Worse Quality of Life)
Symptom Present Symptom Absent
Score n Score n
Edema 48 ± 22 124 32 ± 22 140
Fatigue 44 ± 22 225 16 ± 14 38
Shortness of air 47 ± 22 175 26 ± 19 88
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Table 2
Symptom Frequency by Diet Quality
Worst Diet, % (n = 33) Poor Diet, % (n = 114) Good Diet, % (n = 82) Best Diet, % (n = 19)
Edema 58 50 40 42
Fatigue 94 84 90 63
Shortness of air 70 73 63 37
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Table 3
Quality of Life Scores by Diet Quality (Higher Score = Worse Quality of Life)
Diet Quality n Quality of Life
Worst diet 33 48 ± 22
Poor diet 114 40 ± 23
Good diet 82 37 ± 23
Best diet 19 29 ± 24
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Table 4
Dependent Variables and Measurement
Aim Variable Instrument Times Measured
1 Symptom burden Memorial Symptom Assessment Scale-Heart Failure Baseline, 3, 6, 9, and 12 months
Quality of life Minnesota Living with Heart Failure Questionnaire Baseline, 3, 6, 9, and 12 months
HF hospitalization or all cause
death
Cause of hospitalization and death by monthly patient/family
phone interview and hospital admission/medical record review
3–12 months
2 Dietary sodium intake 24-hour diet recall interview for 2 weekday and 1 weekend day Baseline, 3 and 6 months
Oxidative stress Serum malondialdehyde, PGF2a isoprostane and uric acid Baseline, 3, and 6 months
Inflammation Serum tumor necrosis factor-α; soluble TNF receptors sTNFR1
and sTNFR2; interleukin-10.
Baseline, 3, and 6 months
3 Intervention adherence Fluid balance using body weight; plasma lycopene; erythrocyte
omega-3 index
Baseline, 3, and 6 months
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Table 5
Options for Lycopene Supplementation Component
Intervention Group Choices Lycopene (mg) Usual Care Group Choices Lycopene (mg)
Low sodium tomato juice (8 oz.) 20 100% apple juice (8 oz.) 0
Low sodium V8 juice (11.5 oz.) 24 100% cranberry juice (8 oz.) 0
Low sodium tomato soup (8 oz.) 25 100% orange juice 0
Spaghetti sauce (5 oz.) 25
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